Literature DB >> 28445084

Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations.

Angela Vidal-Jordana1, Jaume Sastre-Garriga1, Deborah Pareto2, Carmen Tur3, Georgina Arrambide1, Susana Otero-Romero1, Elena Huerga2, Raquel Mitjana2, Cristina Auger2, Mar Tintoré1, Alex Rovira2, Xavier Montalban1.   

Abstract

BACKGROUND: Brain atrophy in multiple sclerosis (MS) patients is present since the very early stages of the disease and it has been related to long-term disability.
OBJECTIVE: To estimate brain volume (BV) at 15 years after a clinically isolated syndrome (CIS) and to evaluate its relationship with disease outcomes.
METHODS: From a prospective cohort including patients presenting with a CIS, 54 patients with a brain magnetic resonance imaging (MRI) performed 15 years after CIS were included. Brain parenchymal fraction (BPF), grey matter fraction (GMF) and white matter fraction (WMF) at 15-year follow-up were obtained. Regression analyses were conducted to predict BV loss and reaching an Expanded Disability Status Scale (EDSS) of 3.0 in that 15-year period.
RESULTS: In multivariable analyses, lower values of BPF and WMF were significantly associated with being male, presenting 3-4 Barkhof criteria at baseline, presenting a second relapse, and with a decision to start treatment. In the multivariable logistic regression analysis, only lower GMF was associated with a greater risk of reaching EDSS 3.0 (odds ratio (OR) = 0.24, p = 0.028).
CONCLUSION: Lower BPF and WMF 15 years after CIS are associated with previous markers of inflammatory disease. Lower GMF 15 years after a CIS is associated with an increased risk of reaching an EDSS of 3.0.

Entities:  

Keywords:  Multiple sclerosis; atrophy; clinically isolated syndrome; grey matter

Mesh:

Year:  2017        PMID: 28445084     DOI: 10.1177/1352458517707070

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  2 in total

Review 1.  Drug Treatment of Clinically Isolated Syndrome.

Authors:  Moritz Förster; Jonas Graf; Jan Mares; Orhan Aktas; Hans-Peter Hartung; David Kremer
Journal:  CNS Drugs       Date:  2019-07       Impact factor: 6.497

Review 2.  Magnetic Resonance Imaging as a Prognostic Disability Marker in Clinically Isolated Syndrome and Multiple Sclerosis: A Systematic Review and Meta-Analysis.

Authors:  Amjad I AlTokhis; Abrar AlAmrani; Abdulmajeed Alotaibi; Anna Podlasek; Cris S Constantinescu
Journal:  Diagnostics (Basel)       Date:  2022-01-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.